Athersys

Athersys EBITDA Margin

Delisted·Oct 1, 2026

The EBITDA Margin of Athersys (ATHXQ) as of Nov 20, 2026 is -1,419.51 %. In the previous year, EBITDA Margin was -1,552.92 % — a change of -8.59% (higher).

EBITDA Margin

-1,419.51 %

YoY

-8.59%

Last updated:

EBITDA Margin of Athersys is 2022 -1,419.51 % . EBITDA Margin of Athersys was 2021 -1,552.92 % . It decreases by -8.59% higher compared to the previous year.

The Athersys EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2015
-141.42 USD
Jan 1, 2016
-88.36 USD
Jan 1, 2017
-878.71 USD
Jan 1, 2018
-102.14 USD
Jan 1, 2019
-811.82 USD
Jan 1, 2020
-5,407.96 USD
Jan 1, 2021
-1,552.92 USD
Jan 1, 2022
-1,419.51 USD
The Athersys EBITDA Margin history
YEAREBITDA MarginYoY
-1,419.51 %-8.59%
-1,552.92 %-71.28%
-5,407.96 %+566.15%
-811.82 %+694.80%
-102.14 %-88.38%
-878.71 %+894.49%
-88.36 %-37.52%
-141.42 %-92.00%
-1,768.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys, Inc. generates revenue through the development and commercialization of its MultiStem (invimestrocel) cell therapy, an allogeneic stem cell product candidate derived from adult bone marrow. The company focuses on late-stage clinical development for critical care, neurological conditions, inflammatory disorders, pulmonary conditions, and cardiovascular disease. Its lead product, MultiStem, is currently in Phase III clinical trials for ischemic stroke under the MASTERS-2 study. Athersys targets medical institutions and healthcare providers seeking innovative treatments for unmet medical needs in multiple disease areas. The company's primary product, MultiStem, is manufactured from human stem cells obtained from adult bone marrow and alternative tissue sources. It is designed to address conditions including critical care indications, neurological disorders, inflammatory and immune disorders, pulmonary conditions, and cardiovascular disease. Athersys conducts Phase III trials for ischemic stroke treatment, aiming to secure regulatory approval for broader market access. Revenue streams are expected to emerge post-approval through therapeutic product sales to hospitals and clinics. Athersys, Inc. operates in the biotechnology sector with a focus on regenerative medicine, leveraging its MultiStem platform to address unmet medical needs. The company's clinical development strategy centers on late-stage trials for ischemic stroke and other conditions, targeting healthcare providers and medical institutions as key customers. Commercialization of MultiStem will likely involve partnerships with healthcare systems for treatment protocols and patient access. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

EBITDA Margin of Athersys is -1,419.51 % in 2022.

EBITDA Margin of Athersys changed from -1,552.92 % to -1,419.51 %, representing a -8.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Athersys since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Athersys with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Athersys

All Key Metrics — Athersys